A retrospective cohort study conducted by Ravichandran et al. involving 528 ACS patients with a follow-up period of 6 months demonstrated that NAFLD determined using elevated serum ALT is associated with an increased risk of adverse outcomes and all-cause mortality up to 6 months after discharge with an adjusted OR of 8.96 (95% CI: 3.28–24.49) in ACS patients [35]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.